TECX

Tectonic Therapeutic Inc

Sep 15 • 04:00PM ET

16.59

-1.13 -6.38 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN AMGN GILD BIIB BMRN INCY EXEL NBIX RGEN

| Held by: VTI IWM VXF IWN VTWO IBB IWC IWO DFAS VTWV

Index	RUT	P/E	-	EPS (ttm)	-4.04	Insider Own	43.42%	Shs Outstand	18.71M	Perf Week	1.72%
Market Cap	310.43M	Forward P/E	-	EPS next Y	-4.84	Insider Trans	1.78%	Shs Float	10.59M	Perf Month	-32.20%
Enterprise Value	24.99M	PEG	-	EPS next Q	-1.06	Inst Own	61.20%	Short Float	24.43%	Perf Quarter	-24.21%
Income	-65.98M	P/S	-	EPS this Y	38.91%	Inst Trans	4.19%	Short Ratio	8.18	Perf Half Y	-35.27%
Sales	0.00M	P/B	1.09	EPS next Y	-16.00%	ROA	-26.97%	Short Interest	2.59M	Perf YTD	-64.07%
Book/sh	15.16	P/C	1.08	EPS next 5Y	6.07%	ROE	-29.32%	52W High	61.07 -72.83%	Perf Year	-5.20%
Cash/sh	15.36	P/FCF	-	EPS past 3/5Y	41.06% 26.54%	ROIC	-23.24%	52W Low	13.70 21.09%	Perf 3Y	56.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.27% 8.05%	Perf 5Y	-91.48%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	71.85%	Oper. Margin	-	ATR (14)	1.74	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	25.60	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	35.88	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	25.60	EPS Q/Q	75.35%	SMA20	-21.42%	Beta	1.42	Target Price	79.75
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-23.84%	Rel Volume	0.76	Prev Close	17.72
Employees	51	LT Debt/Eq	0.00	Earnings	Aug 07 AMC	SMA200	-40.43%	Avg Volume	316.33K	Price	16.59
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.47% -	Trades		Volume	239,427	Change	-6.38%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-25	Initiated	Oppenheimer	Outperform	$80
Jul-21-25	Initiated	Truist	Buy	$64
Jun-11-25	Resumed	Raymond James	Outperform	$76
Apr-21-25	Initiated	Mizuho	Outperform	$51
Nov-20-24	Initiated	Raymond James	Outperform	$65
Aug-22-24	Initiated	Wells Fargo	Overweight	$55
Jun-26-24	Initiated	Piper Sandler	Overweight
Jun-24-24	Initiated	TD Cowen	Buy
Dec-18-23	Downgrade	Mizuho	Buy → Neutral
Jan-05-22	Downgrade	BTIG Research	Buy → Neutral
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$24 → $7
Jun-15-21	Initiated	BTIG Research	Buy	$23
May-27-21	Initiated	Needham	Buy	$28
Mar-09-21	Initiated	Barclays	Overweight	$23
Mar-02-21	Initiated	Stifel	Hold	$14
Nov-11-20	Initiated	Berenberg	Buy
Mar-31-20	Downgrade	H.C. Wainwright	Buy → Neutral	$13
Jun-27-19	Initiated	Mizuho	Buy	$28
Apr-05-19	Initiated	Janney	Buy
Oct-10-18	Initiated	Guggenheim	Buy

Show Previous Ratings

Aug-28-25 09:00AM	Tectonic Therapeutic to Participate in September Investor Conferences (GlobeNewswire)
Aug-07-25 04:01PM	Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -5.35%
Jun-30-25 08:00AM	Tectonic Therapeutic Joins Russell 3000 Index (GlobeNewswire)
Jun-24-25 05:42PM	Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating (Insider Monkey) +7.57%
May-17-25 10:40AM	Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 (GlobeNewswire)
09:55AM	Loading…
May-13-25 09:55AM	Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High? (Zacks)
May-08-25 04:01PM	Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +10.81% -5.99%
May-07-25 08:00AM	Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference (GlobeNewswire)
May-01-25 05:59AM	TipRanks Perfect 10 Picks: 2 Top-Scoring Stocks Earning Wall Streets Seal of Approval (TipRanks) -5.75%
Apr-23-25 05:51AM	Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF (Seeking Alpha)
Apr-15-25 08:00AM	Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025 (GlobeNewswire)
Mar-20-25 04:01PM	Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-04-25 08:26PM	Is Tectonic Therapeutic, Inc. (TECX) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
Feb-20-25 08:00AM	Tectonic Therapeutic to Participate in March Investor Conferences (GlobeNewswire)
Feb-03-25 06:30AM	Tectonic Announces $185 Million Private Placement (GlobeNewswire) -6.52%
06:30AM	Loading…
Jan-30-25 06:30AM	Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF (GlobeNewswire) +113.22%
Dec-03-24 04:01PM	Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024 (GlobeNewswire)
Nov-26-24 04:01PM	Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-12-24 11:01PM	Tectonic Therapeutic Inc. Reports Q3 2024 Results (TipRanks)
Nov-11-24 05:00AM	Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein (GlobeNewswire)
Nov-07-24 04:01PM	Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-22-24 04:01PM	Tectonic Therapeutic to Present Phase 1a Data at AHA 2024 (GlobeNewswire)
Sep-19-24 04:01PM	Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 (GlobeNewswire)
Aug-20-24 04:01PM	Tectonic Therapeutic to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-24 04:01PM	Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +5.23%
Jul-30-24 04:01PM	Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45 (GlobeNewswire)
Jun-20-24 04:01PM	Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million (Business Wire)
09:47AM	PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML (InvestorPlace)
08:26AM	Why Is Avrobio (AVRO) Stock Moving Today? (InvestorPlace)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
11:27AM	Loading…
May-15-24 11:27AM	Avrobio Insider Bought Shares Worth $971,493, According to a Recent SEC Filing (MT Newswires) +6.20%
May-13-24 09:53AM	AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024 (InvestorPlace) +9.76%
Feb-27-24 10:50AM	Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm (PR Newswire)
Feb-01-24 02:25PM	Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm (PR Newswire)
Jan-31-24 10:40AM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates TAST, AVRO, CALB (GlobeNewswire) +9.57%
06:42AM	Avrobios road ends in reverse merger with Tim Springer-backed startup (BioPharma Dive)
Jan-30-24 02:52PM	Avrobio's corporate tremor attracts Tectonic for reverse merger (FierceBiotech.com) -16.06%
02:38PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCAL (PR Newswire)
08:00AM	AVROBIO and Tectonic Therapeutic Announce Merger (Business Wire)
Nov-08-23 09:40AM	Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-23-23 09:40AM	Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-06-23 09:40AM	Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-13-23 07:08AM	AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46% (Zacks)
Jul-12-23 07:00AM	AVROBIO to Explore Strategic Alternatives (Business Wire) +45.96%
Jun-12-23 07:00AM	AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million (Business Wire)
May-22-23 07:00AM	AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million (Business Wire) +69.01%
May-18-23 02:53PM	Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months (Benzinga) +45.33%
07:00AM	AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting (Business Wire)
May-11-23 07:00AM	AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-01-23 07:30AM	AVROBIO Announces Leadership Transition (Business Wire) -15.99%
Mar-23-23 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update (Business Wire) -27.64%
Mar-03-23 07:00AM	AVROBIO to Participate in Cowens 43rd Annual Health Care Conference (Business Wire)
Feb-09-23 07:00AM	AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium 2023 (Business Wire) +7.69%
Jan-05-23 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-07-22 07:30AM	AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy (Business Wire) -6.96%
Nov-17-22 07:00AM	AVROBIO to Share Comprehensive Gaucher Disease Program Update (Business Wire) +5.40%
Nov-08-22 07:00AM	AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-07-22 07:00AM	AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit (Business Wire)
Nov-03-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-27-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire)
Oct-25-22 07:00AM	AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis (Business Wire)
Oct-18-22 07:00AM	AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire) +12.37%
Oct-11-22 07:00AM	AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development (Business Wire)
Oct-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-27-22 07:00AM	AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress (Business Wire) -10.23%
Sep-20-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis (Business Wire)
Sep-14-22 07:28AM	AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial (Business Wire)
Sep-08-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-31-22 07:00AM	AVROBIO to Participate in Four Upcoming Investor Conferences in September (Business Wire)
Aug-09-22 07:00AM	AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Aug-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-22 07:00AM	AVROBIO to Participate in Two Upcoming Investor Conferences in August (Business Wire)
Jul-13-22 07:00AM	AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome (Business Wire)
Jul-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.47%
May-18-22 03:12PM	AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study (Zacks) -8.57%
12:41PM	Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study (Benzinga)
07:00AM	AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (Business Wire)
May-17-22 12:15PM	AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study (Benzinga)
07:00AM	AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures (Business Wire)
May-16-22 07:00AM	AVROBIO to Present at the H.C. Wainwright Global Investment Conference (Business Wire)
May-10-22 07:00AM	AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire)
May-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-03-22 07:00AM	AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting (Business Wire)
Apr-06-22 12:36PM	bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn (Zacks)
07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-05-22 12:54PM	Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study (Zacks)
07:00AM	AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-17-22 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update (Business Wire) +8.33%
Mar-01-22 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences in March (Business Wire)
Feb-21-22 12:14PM	2 Net Current Asset Value Stocks to Consider (GuruFocus.com)
Feb-09-22 12:55PM	After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data (Benzinga) -6.25%
07:00AM	AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis (Business Wire)
Feb-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-03-22 10:00AM	Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks (Zacks)
Feb-01-22 07:00AM	AVROBIO Announces the Appointment of Sean OBryan as Chief Regulatory Officer (Business Wire)
Jan-28-22 07:00AM	AVROBIO to Present at Cowens 2nd Annual Genetic Medicines Summit (Business Wire) +6.32%
Jan-27-22 07:00AM	AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium 2022 (Business Wire) -5.43%
Jan-25-22 10:00AM	Bears are Losing Control Over AVROBIO, Inc. (AVRO), Here's Why It's a 'Buy' Now (Zacks)
Jan-07-22 10:00AM	Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 44.1% in 4 Weeks (Zacks)
Jan-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	16.31	53,706	875,945	1,503,358	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	16.73	45,858	767,204	1,449,652	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	14.76	21,071	311,020	1,403,794	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	16.31	9,478	154,586	4,334,846	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	16.73	8,092	135,379	4,325,368	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	14.76	3,718	54,880	4,317,276	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 07 '25	Buy	17.10	412,500	7,053,750	1,382,723	Apr 09 05:38 PM
SPRINGER TIMOTHY A	Director	Apr 07 '25	Buy	17.10	87,500	1,496,250	4,313,558	Apr 09 05:38 PM
MCGUIRE TERRANCE	Director	Apr 07 '25	Sale	17.10	500,000	8,550,000	573,062	Apr 07 05:02 PM
SPRINGER TIMOTHY A	Director	Feb 05 '25	Buy	50.00	660,000	33,000,000	970,223	Feb 07 04:21 PM
SPRINGER TIMOTHY A	Director	Feb 05 '25	Buy	54.14	129,294	6,999,977	4,226,058	Feb 07 04:21 PM
Lochner Daniel	Chief Financial Officer	Feb 05 '25	Buy	54.14	4,617	249,964	4,617	Feb 07 04:19 PM
Schwabish Marc	Chief Business Officer	Jan 28 '25	Option Exercise	2.38	2,700	6,426	4,700	Jan 29 04:05 PM
Schwabish Marc	Chief Business Officer	Dec 09 '24	Option Exercise	2.38	2,000	4,760	2,000	Dec 11 04:21 PM
McNamara Peter	Chief Scientific Officer	Dec 03 '24	Option Exercise	2.38	3,500	8,330	14,188	Dec 05 04:32 PM
SPRINGER TIMOTHY A	Director	Oct 22 '24	Buy	33.59	300,000	10,077,000	4,096,764	Oct 24 05:04 PM
SPRINGER TIMOTHY A	Director	Sep 26 '24	Buy	28.82	50,000	1,440,829	3,796,764	Sep 26 06:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TECX

Tectonic Therapeutic Inc

Upgrade your FINVIZ experience